MRgFUS Versus EBRT in Patients With Metastatic Non-spinal Bone Disease

Status Completed

Clinical Trial Summary

The objective of this trial is to collect and compare safety and effectiveness data of Magnetic Resonance guided Focused Ultrasound (MRgFUS) using the ExAblate 2100 device and radiotherapy in the treatment of metastatic bone tumors. This study is designed as a prospective, double arm, non-randomized study with External Beam radiation therapy (EBRT) serving as control arm. The study hypothesis is that MRgFUS is an effective non-invasive and safe treatment for the palliation of metastatic bone tumors with a low incidence of co-morbidity as compared to EBRT.

Clinical Trial Description

This is a prospective, phase II, open-label, non-randomized, double arm study to collect data on safety and effectiveness of ExAblate MRgFUS and EBRT treatments of metastatic bone tumors. Following treatment assignment and treatment itself, subjects will be followed for up for 12 months to evaluate pain relief as well as quality of life. Additional data regarding dosage and frequency of analgesic consumption for the management of the bone tumor induced pain will also be collected. MRI of the treated lesion will be obtained 3 and 6 months post therapy to evaluate effect on the lesion in both radiation and MRgFUS arms. This is clinically acceptable and widely utilized diagnostic method in follow up of this patient population. Data will be collected for a total of 184 patients, 92 patients treated by EBRT and another 92 patients treated by FUS. Treating physician, as of his/her normal practice, might offer additional treatment of other type in cases where pain score of the treated lesion will not improve by at least 2 points, and will remain 4 or greater. Additional treatment may be performed up to one month following treatment. Prior to offering alternative treatment, an MRI will be performed to evaluate effect on the lesion. Patient receiving another treatment, different from the initial one (i.e. patient initially treated with FUS is now treated by EBRT) will be considered as treatment failures for the primary analysis and their post-x-over follow-up results will be analyzed separately. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03404362
Study type	Interventional
Source	University of Roma La Sapienza
Contact
Status	Completed
Phase	N/A
Start date	January 2017
Completion date	September 2020

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03986593` - Cryoablation of Bone Metastases From Endocrine Tumors	N/A
Active, not recruiting	`NCT01996046` - FDG PET/CT in Breast Cancer Bone Mets
Completed	`NCT01358539` - Palliation: the Effect of Education on Pain	Phase 3
Terminated	`NCT00981578` - ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain	N/A
Terminated	`NCT00757757` - A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases	Phase 1/Phase 2
Completed	`NCT00762346` - Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis	Phase 4
Completed	`NCT00420433` - Bone Response in Metastatic Breast Cancer Involving Bones	N/A
Completed	`NCT02826382` - Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041	Early Phase 1
Terminated	`NCT05301062` - A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
Recruiting	`NCT06367491` - National Database of Bone Metastases
Completed	`NCT03223727` - Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223
Completed	`NCT00830180` - Open Label Extension In Cancer Patients	Phase 2
Active, not recruiting	`NCT03305224` - The Combination Therapy With Ra-223 and Enzalutamide	Phase 2
Withdrawn	`NCT04109937` - External Beam Radiation Therapy Post Surgery in Patients With Lower Extremity Bone Metastases Randomized Efficacy Trial	N/A
Active, not recruiting	`NCT02880943` - Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)	Phase 1/Phase 2
Completed	`NCT01696760` - Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology	N/A
Completed	`NCT00958477` - A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer	Phase 1
Completed	`NCT03979118` - Exercise Prescription in Patients With Bone Metastases
Completed	`NCT03353090` - Double-bed SPECT/CT for Bone Scintigraphy in Initial Staging of Cancer Patients	N/A
Recruiting	`NCT05167669` - Pain Relief in Symptomatic Bone Metastases With Adjuvant Hyperthermia MR Guided HIFU	Early Phase 1